FDA flags potential vision loss risk linked to GLP-1 drugs: What users of weight-loss medications should know
LiveMint

An FDA analysis found a potential risk of vision loss associated with GLP-1 weight-loss drugs.
An FDA analysis reviewing 126 clinical trials involving 134,253 participants has revealed a higher incidence of NAION among users of GLP-1 drugs. This potential vision loss risk compares GLP-1 users against those taking placebos or alternative diabetes medications. The findings highlight new safety considerations for individuals using these popular weight-loss medications.
Why it matters: The findings highlight a potential severe medical risk associated with widely used weight-loss and diabetes medications, which could impact patient safety guidelines.


